ACTRN12608000403336
Active, not recruiting
Not Applicable
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone to establish disease-free survival outcomes in locally advanced rectal cancer (PETACC-6)
Australasian Gastro-Intestinal Trials Group (AGITG)0 sites1,090 target enrollmentAugust 18, 2008
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Rectal cancer
- Sponsor
- Australasian Gastro-Intestinal Trials Group (AGITG)
- Enrollment
- 1090
- Status
- Active, not recruiting
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Male or female patients with histologically proven adenocarcinoma of the rectum (tumour \= 12 cm from the anal verge as assessed by rigid proctoscopy)
- •2\.T3/4 or any node\-positive disease
- •3\.No evidence of metastatic disease
- •4\.The disease must be considered either resectable at the time of entry or expected to become resectable after preoperative chemoradiation.
- •5\.Age \= 18 years.
- •6\.World Health Organisation (WHO) / Eastern Cooperative Oncology Group (ECOG) Performance Status \= 2
- •7\.No prior cytotoxic chemotherapy or radiotherapy for rectal cancer.
- •8\.No prior radiotherapy of the pelvis, for any reason.
- •9\.Presence of adequate contraception in fertile patients. Pregnant or breastfeeding women are excluded from participation.
- •10\.Adequate bone marrow, hepatic and renal function:
Exclusion Criteria
- •1\. Pregnant or breastfeeding women or fertile patients not using adequate contraception.
- •2\.Prior cytotoxic chemotherapy or radiotherapy for rectal cancer.
- •3\.Prior radiotherapy of the pelvis, for any reason.
- •4\. Previous (within the last 5 years) or concurrent malignancies.
- •5\.Clinically significant (i.e. active) cardiac disease (e.g. congestive heart failure, symptomatic coronary artery disease and cardiac arrhythmia not well controlled with medication) or myocardial infarction within the last 12 months.
- •6\.Significant impairment of intestinal resorption (e.g. chronic diarrhoea, inflammatory bowel disease).
- •7\.Pre\-existing condition which would deter chemoradiotherapy or radiotherapy, i.e. fistulas, severe ulcerative colitis (particularly patients currently taking Sulphasalazine), Crohn’s disease, prior adhesions.
- •8\.Peripheral neuropathy \= grade 2 (according to Common Terminology Criteria for Adverse Events (CTCAE) v3\.0\).
- •9\.History of uncontrolled seizures, central nervous system disorders or psychiatric disability judged by the investigator to be clinically significant precluding informed consent or interfering with compliance for oral drug intake.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
clinical study to evaluate the efficacy of a two drug combination versus a single drug therapy in the treatment of locally advanced rectal cancer.locally advanced rectal cancerMedDRA version: 17.0Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 17.0Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2006-006532-21-DEEORTC1,094
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) - PETACC-6locally advanced rectal cancerMedDRA version: 9.1Level: LLTClassification code 10038050Term: Rectal cancer stage IIIMedDRA version: 9.1Level: LLTClassification code 10038049Term: Rectal cancer stage IIEUCTR2006-006532-21-FREORTC1,090
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6) - PETACC-6locally advanced rectal cancerMedDRA version: 9.1 Level: LLT Classification code 10038050 Term: Rectal cancer stage IIIMedDRA version: 9.1 Level: LLT Classification code 10038049 Term: Rectal cancer stage IIEUCTR2006-006532-21-GBEuropean Organization for Research and Treatment of Cancer1,094
Active, not recruiting
Phase 1
Preoperative chemoradiotherapy and postoperative chemotherapy with capecitabine and oxaliplatin vs. capecitabine alone in locally advanced rectal cancer (PETACC-6)locally advanced rectal cancerMedDRA version: 14.1Level: PTClassification code 10038050Term: Rectal cancer stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 14.1Level: PTClassification code 10038049Term: Rectal cancer stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2006-006532-21-BEEORTC1,090
Recruiting
Not Applicable
Effect of preoperative concurrent chemoradiotherapy in patients with adenocarcinoma of esophagusHealth Condition 1: null- patients with ECOG (0,1,2) - Good performance statusCTRI/2013/09/003981not applicable160